Franiel T, Röthke M
Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland.
CONRADIA Radiologie und Nuklearmedizin, MVZ Conradia GmbH, Alte Holstenstraße 16, 21031, Hamburg, Deutschland.
Radiologe. 2017 Aug;57(8):665-678. doi: 10.1007/s00117-017-0269-0.
The PI-RADS 2.0 classification was established by an international collaboration of the European Society of Urogenital Radiology (ESUR), the American College of Radiology (ACR), and AdMetech Foundation to globally standardize the acquisition and interpretation of multiparametric prostate magnetic resonance imaging (MRI). The PI-RADS 2.0 aims to improve the detection, localization, staging and risk stratification of patients with suspected or histologically confirmed prostate cancer. Suspicious areas on T2-weighted (T2w) MRI, diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) were assessed for the presence of a clinically significant prostate cancer with scale from 1 to 5 with 5 being most likely to represent clinically significant prostate cancer. The dominant sequence to detect significant prostate cancer in the peripheral zone is DWI and for the transition zone T2w images. For the local staging of prostate cancer criteria for the assessment of an extracapsular growth were formulated.
前列腺影像报告和数据系统(PI-RADS)2.0分类由欧洲泌尿生殖放射学会(ESUR)、美国放射学会(ACR)和AdMetech基金会通过国际合作制定,旨在使多参数前列腺磁共振成像(MRI)的采集和解读在全球范围内标准化。PI-RADS 2.0旨在改善疑似或经组织学证实的前列腺癌患者的检测、定位、分期和风险分层。对T2加权(T2w)MRI、扩散加权MRI(DWI)和动态对比增强MRI(DCE-MRI)上的可疑区域进行评估,以确定是否存在临床显著性前列腺癌,评分为1至5分,5分最有可能代表临床显著性前列腺癌。检测外周区显著性前列腺癌的主要序列是DWI,而移行区则是T2w图像。针对前列腺癌的局部分期,制定了评估包膜外生长的标准。